Program
mtbvac
Its studies are mostly in Tuberculosis, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Biofabri, S.L | 31 open or running | phase 3since Jun 21, 2021 | Mar 15, 2016 | Feb 2029phase 3 · NCT04975178 |
| Bharat Biotech International | 11 open or running | phase 2since May 14, 2025 | May 14, 2025 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 15, 2016First study: phase 2 study in TuberculosisNew to Biofabri, S.LBiofabri, S.L · NCT02729571 · 54 enrolled · South Africa
- Feb 16, 2018Phase 2 study in TuberculosisBiofabri, S.L · NCT03536117 · 99 enrolled · South Africa
- Jun 21, 2021Phase 3 study in TuberculosisBiofabri, S.L · NCT04975178 · 7,120 planned · South Africa
- May 14, 2025Bharat Biotech International's first study: phase 2 study in TuberculosisNew to Bharat Biotech InternationalBharat Biotech International · NCT06997367 · 164 enrolled · India
Ahead
- Feb 2029Primary completion: phase 3 study in TuberculosisBiofabri, S.L · NCT04975178
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06997367Tuberculosis · India | 2 | Active, not recruiting | Bharat Biotech International | Sep 1, 2025 | 164 |
| NCT04975178Tuberculosis · South Africa | 3 | Recruiting | Biofabri, S.L | Feb 2029 | 7,120 |
| NCT03536117Tuberculosis · South Africa | 2 | Completed | Biofabri, S.L | May 17, 2022 | 99 |
| NCT02729571Tuberculosis · South Africa | 2 | Completed | Biofabri, S.L | Sep 2016 | 54 |
How it is read
Names in the registry
- “MTBVAC”, 4 entries
Conditions, from the studies’ own filings
- Tuberculosis, 4 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.